Cell Medica, a leader in developing, marketing and manufacturing cellular therapeutics for cancer and viral infections, announced today the acquisition of Delenex Therapeutics AG, a privately held, clinical stage biopharmaceutical company focused on the development of locally and systemically applied antibody therapeutics.<\/p>\n\n\n\n
The acquisition will enable Cell Medica to accelerate the development of gene-modified immune cell products with enhanced potency for the treatment of cancer. Delenex\u2019s proprietary PENTRA\u00ae technology allows the rapid development of antibody therapeutics within a humanized framework. The Delenex technology and expertise will be integrated with Cell Medica\u2019s product development programme aimed at creating next generation Chimeric Antigen Receptor (CAR)-modified cellular immunotherapies with improved functionality and specificity. Financial details were not disclosed.<\/p>\n\n\n\n
Delenex was founded in September 2009 as a spin-off from ESBATech (now a Novartis company). The Delenex scientific team and laboratory facilities based in Schlieren, Switzerland will form a key part of Cell Medica\u2019s international R&D operations and will be re-named Cell Medica Switzerland AG.<\/p>\n\n\n\n
Gregg Sando, CEO of Cell Medica<\/strong>, said:<\/p>\n\n\n\n \u201cWe are committed to transforming the treatment of cancer through the significant therapeutic potential of cellular immunotherapy. The acquisition of Delenex provides a key enabling technology for the development of an exciting pipeline of next generation CAR-modified cell therapies. We are delighted to welcome the talented team from Delenex and to join the vibrant Swiss biotech community based in Schlieren.\u201d<\/em><\/p>\n","protected":false},"excerpt":{"rendered":" Cell Medica, a leader in developing, marketing and manufacturing cellular therapeutics for cancer and viral infections, announced today the acquisition of Delenex Therapeutics AG, a privately held, clinical stage biopharmaceutical company focused on the development of locally and systemically applied antibody therapeutics. The acquisition will enable Cell Medica to accelerate the development of gene-modified immune Read the full article…<\/a><\/p>\n","protected":false},"author":3,"featured_media":191,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"aside","meta":[],"categories":[8,3,5],"tags":[],"_links":{"self":[{"href":"https:\/\/design4paper.com\/vipartners-test-live\/wp-json\/wp\/v2\/posts\/703"}],"collection":[{"href":"https:\/\/design4paper.com\/vipartners-test-live\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/design4paper.com\/vipartners-test-live\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/design4paper.com\/vipartners-test-live\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/design4paper.com\/vipartners-test-live\/wp-json\/wp\/v2\/comments?post=703"}],"version-history":[{"count":1,"href":"https:\/\/design4paper.com\/vipartners-test-live\/wp-json\/wp\/v2\/posts\/703\/revisions"}],"predecessor-version":[{"id":704,"href":"https:\/\/design4paper.com\/vipartners-test-live\/wp-json\/wp\/v2\/posts\/703\/revisions\/704"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/design4paper.com\/vipartners-test-live\/wp-json\/wp\/v2\/media\/191"}],"wp:attachment":[{"href":"https:\/\/design4paper.com\/vipartners-test-live\/wp-json\/wp\/v2\/media?parent=703"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/design4paper.com\/vipartners-test-live\/wp-json\/wp\/v2\/categories?post=703"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/design4paper.com\/vipartners-test-live\/wp-json\/wp\/v2\/tags?post=703"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}